Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65.
Robert BuynakKevin CannonDavid DeAtkineJohn KirbyLisa UsdanAmit B BhavsarCatherine GérardAnastasia KuznetsovaAmulya JayadevHiwot AmareSofia ValencianoNadia MeyerPublished in: Infectious diseases and therapy (2024)
ClinicalTrials.gov identifier, NCT05559476.